Tekmira Announces Proposed Public Offering of Common Stock
16 oct. 2013 16h01 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Provides Corporate Update on RNAi Therapeutics Pipeline
08 oct. 2013 16h00 HE
|
Arbutus Biopharma Corporation
Tekmira Builds Upon Extensive Experience in Anti-Viral Therapeutics by Adding Therapeutics Addressing Hepatitis B and Marburg Virus to Product Pipeline
TKM-ALDH2, an RNAi Therapeutic for Alcohol...
Tekmira Appoints Bruce Cousins as Executive Vice President and Chief Financial Officer
07 oct. 2013 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, B.C., Oct. 7, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today that Mr....
Tekmira Presents TKM-PLK1 Data at 6th Annual North American Neuroendocrine Tumor Society (NA-NETS) Conference
04 oct. 2013 08h00 HE
|
Arbutus Biopharma Corporation
New Data Shows Positive Chromogranin-A Biomarker Results in GI-NET Patient
Phase I/II Clinical Trial with TKM-PLK1 Ongoing in Patients with Advanced Gastrointestinal Neuroendocrine Tumors (GI-NET)...
Tekmira to Host Research and Development Webinar Providing Corporate Update on Product Pipeline
03 oct. 2013 08h30 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Oct. 3, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics announced that...
Tekmira Presents New Anti-Viral Efficacy Data Against the Marburg Hemorrhagic Fever Virus
25 sept. 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced...
Tekmira Provides Update on Licensed Product Candidate, Marqibo(R)
03 sept. 2013 17h42 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Sept. 3, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, disclosed that...
Tekmira's Lipid Nanoparticle (LNP) Technology Highlighted in Two Peer-Reviewed Scientific Publications
30 août 2013 08h00 HE
|
Arbutus Biopharma Corporation
Published Data Shows 100% Protection Against Multiple Strains of Marburg Virus in Animal Model Using RNAi Therapeutic Developed by Tekmira and Its Collaborators
ALN-TTR Results Enabled by...
Tekmira Provides Corporate Update and Announces Second Quarter 2013 Results
12 août 2013 16h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced...
Tekmira Strengthens Development Team With Appointment of Dr. Mark Kowalski as Chief Medical Officer
12 août 2013 08h00 HE
|
Arbutus Biopharma Corporation
VANCOUVER, British Columbia, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced today...